Epigenomic alterations contribute to obesity-associated diabetes

June 08 2016

Obesity is a risk factor for developing type 2 diabetes, yet not all obese humans develop the disease. In a new study, researchers from the Karolinska Institutet in Sweden and from the Institute of Health and Medical Research (INSERM) in France have identified epigenomic alterations that are associated with inflammation and type 2 diabetes. The findings, which are published in the journal Nature Medicine, help to explain how alterations of the epigenome during the progression of obesity can trigger insulin resistance and diabetes.

Obese individuals differ in their susceptibility to developing insulin resistance and diabetes. Researchers believe that changes in the epigenome could be an important reason behind this difference. Epigenetic alterations increase or decrease gene expression by coupling different kinds of chemical flags to the DNA and to the histone proteins that constitute the chromatin. In contrast to the genes themselves, epigenetic alterations are dynamic and can be altered by environmental influences and nutritional components.

The research team, led by Eckardt Treuter and Nicolas Venteclef, were interested in a so-called co-repressor complex that can modify chromatin epigenetically. This particular complex contains GPS2 (G-protein pathway suppressor 2). The study reveals a key role of the GPS2 complex in controlling the epigenome in macrophages. Macrophages play a central role in the immune defense, but are also involved in the metabolically-triggered low-grade inflammation associated with metabolic diseases, including obesity and type 2 diabetes.

Initially, the INSERM team had found that GPS2 levels are reduced in the adipose tissue in obese people with diabetes, as compared to non-diabetic people. As it turned out, the identified obesity-associated alterations are conserved between humans and mice. The Karolinska team had generated mice that lack GPS2 in macrophages. When fed with a high-fat diet, these genetically modified mice did not become more obese than normal mice. However, they developed complications such as adipose tissue inflammation, systemic insulin resistance, and fatty liver, more rapidly. The characteristics observed in these mice mirror the human situation of “metabolically healthy” versus “unhealthy obese” people, according to the authors.

”The findings point to a causal and potentially reversible relationship between inappropriate expression and function of the complex, the extent of adipose tissue inflammation, and systemic insulin resistance towards type 2 diabetes”, says Nicolas Venteclef at the Cordeliers Research Centre, INSERM, in Paris.

”The study highlights the value of combining mouse and human studies in identifying molecular mechanisms underlying disease”, says Eckardt Treuter at Karolinska Institutet’s Department of Biosciences and Nutrition in Huddinge, South Stockholm. ”In particular, the mouse experiments provide strong evidence that epigenome alterations that originate in either macrophages or fat cells can be the cause, and not just a consequence, of obesity complications towards diabetes.”

The investigators believe that these alterations could be part of an ’epigenetic memory’ that can speed up an inflammatory response under conditions of metabolic stress linked to obesity and diabetes.

The research was supported by grants from, among others, the Swedish Research Council, the French National Agency of Research, the Swedish Cancer Society, the French Foundation for Medical Research, the Novo Nordisk Foundation and the Swedish Diabetes Foundation and the French and European Diabetes Foundations.


Back to release list of thematic

Know more

Sources

Loss of the co-repressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type-2 diabetes.
Rongrong Fan 1,#, Amine Toubal 2,3,#, Saioa Goñi 1,#, Karima Drareni 2,3, Zhiqiang Huang 1, Fawaz Alzaid 2,3, Raphaelle Ballaire 2,3, Patricia Ancel 4, Ning Liang 1, Anastasios Damdimopoulos 1, Isabelle Hainault 2,3, Antoine Soprani 2,5, Judith Aron-Wisnewsky 3,6,7, Fabienne Foufelle 2,3, Toby Lawrence 8,9,10, Jean-Francois Gautier 2,11, Nicolas Venteclef 2,3, #,* & Eckardt Treuter 1,#,*

1 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden.
2 Sorbonne Universités, Université Pierre et Marie-Curie, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR_S 1138 Cordeliers Research, Paris, France,
3 Institute of Cardiometabolism and Nutrition, Paris, France,
4 Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1062, INRA 1260, Aix-Marseille Université, Nutrition, Obésité et Risque Thrombotique, Marseille,
5 Clinique Geoffroy Saint-Hilaire, General de Santé, Paris, France,
6 Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Heart and Metabolism Division, Paris, France,
7 Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Universités, Université Pierre et Marie-Curie (UPMC), UMR_S U1166, NutriOmics team, Paris, France ;
8 Centre d’Immunologie de Marseille-Luminy (CIML), Aix-Marseille Université, UM2, Marseille, France.
9 Institut National de la Santé et de la Recherche Médicale (INSERM), U1104, Marseille, France.
10 Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.
11 Assistance Publique-Hôpitaux de Paris, Lariboisière Hospital, Department of Diabetes, Clinical Investigation Centre (CIC-9504), University Paris-Diderot, Paris, France

Nature Medicine june 6 2016 http://dx.doi.org/10.1038/nm.4114

Researcher Contact

Eckardt Treuter, Professor 
Department of Biosciences and Nutrition, Karolinska Institutet
Telephone: +46 (0)8-524 810 60 or +46-(0)70-7563805
Profile page: http://ki.se/en/people/ecktre

Nicolas Venteclef, Associate Professor
Institute of Health and Medical Research UMR1138
Centre de Recherche des Cordeliers, UMR_S 1138
Type-2 diabetes pathogenesis
Telephone: +33.(0)1.44.27.24.31
Profile page: http://www.crc.jussieu.fr/en/fabienne_foufelle_eng.html

Press Contact

presse@inserm.fr

^ Top of page
View Edit Create here